Biopharmaceutical News and Research

RSS

Sosei R&D enters agreement with Pharmasol R&D to assign its rights to the assets of AD 923

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei R&D Ltd., its wholly owned UK subsidiary, has entered into an agreement to assign its rights to the assets of AD 923, an optimised, sublingual formulation of the opioid analgesic fentanyl for the treatment of cancer breakthrough pain, as well as to the device for drug administration to Pharmasol R&D Ltd., a privately held UK company.

6 Oct 2009

St. Jude Children’s Research Hospital researcher receives the Millipore Guava Flow Cytometry Award

Millipore Corporation, a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today awarded Dr. Mari Hashitate Dallas of St. Jude Children’s Research Hospital in Memphis, Tenn., the Millipore Guava® Flow Cytometry Award.

6 Oct 2009

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

Sequella receives ARRA funds to manufacture SQ109 for treating tuberculosis

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $694,000 grant supplement as part of the American Recovery and Reinvestment Act (ARRA) of 2009.

6 Oct 2009

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

The Centre for Blood Research (CBR) and the Faculty of Medicine at the University of British Columbia have announced the establishment of the CSL Behring - Canada Research Chair in Endothelial Cell Biology. Over the next five years, the CBR and CSL Behring Canada, the biopharmaceutical company co-funding the chair program, will collaborate on the research and development of new therapies for patients with bleeding and immune system disorders.

5 Oct 2009

Rxi Pharmaceuticals to ring Nasdaq closing bell in NYC's Times Square

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that Tod Woolf, Ph.D., President and CEO, along with members of RXi’s management team, will ring the Nasdaq closing bell tomorrow, Tuesday, Oct 6, 2009 at the Nasdaq Marketsite in New York City’s Times Square.

5 Oct 2009

Genentech is again the world's most respected biopharmaceutical employer

Science annual survey of Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries. Respondents to the web-based survey are asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change, and a research-driven environment.

5 Oct 2009

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented 'The JCA-Mauvernay Award' to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the "epigenetic field for cancerization".

5 Oct 2009

Diagnocure signs agreement with Lab21 for marketing its Previstage test

DiagnoCure Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland.

5 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

Chinese government places second purchase order for Sinovac Biotech's H1N1 vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac has received its second purchase order for its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and Information Technology of the People's Republic of China for the national stockpiling plan.

3 Oct 2009

DelSite's assests acquired by Nanotherapeutics

Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced today that it had acquired certain assets from DelSite (formerly Carrington Laboratories, Inc.) out of Chapter 7 bankruptcy proceedings in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division.

3 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Raptor and TorreyPines Therapeutics announce merger completion

Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger.

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

CBR Pharma reports on M&A in the biopharmaceutical industry

The history of the pharmaceutical industry is closely linked to the business practices of the combination and purchase of corporations. From the creation of the combined entity of Warner-Lambert in 1955, to the purchase of Warner-Lambert by Pfizer in 2000, to the recent acquisition of Wyeth, pharmaceutical and biotech companies have expanded their pipelines, portfolios, and sales forces through mergers and acquisitions (M&A).

30 Sep 2009

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint.

30 Sep 2009

NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Massachusetts General Hospital (MGH), in collaboration with Novelos, was awarded a $950,371 competitive grant by the National Institutes of Health (NIH) to study two Novelos compounds – NOV-002 and NOV-205 – for the mitigation and treatment of radiation-induced pulmonary injury.

29 Sep 2009

Renewed GMP certification for China Biologic Products' Qianfeng subsidiary

China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.

29 Sep 2009

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule.

29 Sep 2009

Biopharmaceutical News and Research

Sosei R&D enters agreement with Pharmasol R&D to assign its rights to the assets of AD 923

St. Jude Children’s Research Hospital researcher receives the Millipore Guava Flow Cytometry Award

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

Sequella receives ARRA funds to manufacture SQ109 for treating tuberculosis

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

Rxi Pharmaceuticals to ring Nasdaq closing bell in NYC's Times Square

Genentech is again the world's most respected biopharmaceutical employer

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Diagnocure signs agreement with Lab21 for marketing its Previstage test

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

Chinese government places second purchase order for Sinovac Biotech's H1N1 vaccine

DelSite's assests acquired by Nanotherapeutics

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Raptor and TorreyPines Therapeutics announce merger completion

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

CBR Pharma reports on M&A in the biopharmaceutical industry

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury

Renewed GMP certification for China Biologic Products' Qianfeng subsidiary

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News